Toragen is focused on developing, repurposing and commercializing uniquely selective cancer drugs targeting cancers caused by the human papillomavirus (“HPV”). HPV associated cancers include Head and Neck Cancer, Cervical Cancer, and multiple other Genitourinary and Gastrointestinal Cancers. Our drugs are designed to inhibit HPV oncogenes, the root cause of malignant transformation in these cancers.